About Oncol.net

Our Mission

To provide accurate, accessible, and actionable oncology information to patients, caregivers, and healthcare professionals worldwide.

Who We Are

Oncol.net is a comprehensive oncology knowledge hub dedicated to delivering medically-reviewed, evidence-based cancer information. Founded in 2026, we bridge the gap between complex medical literature and practical, understandable guidance for those affected by cancer.

Our content is created by medical writers with expertise in oncology and reviewed by board-certified oncologists, ensuring accuracy while maintaining accessibility for diverse audiences.

Our Values

🎯 Accuracy

Every piece of content undergoes rigorous medical review to ensure factual correctness and alignment with current medical guidelines.

📚 Accessibility

Complex medical information presented in clear, understandable language without sacrificing scientific accuracy.

🔄 Currency

Regular content updates to reflect the latest advances in oncology research and treatment guidelines.

⚖️ Objectivity

Unbiased presentation of treatment options and medical information, free from commercial influence.

Medical Review Board

Our Medical Review Board consists of experienced oncologists, oncology nurses, and healthcare professionals who ensure all content meets the highest standards of medical accuracy.

Dr. Sarah Johnson, MD

Board-Certified Medical Oncologist
Fellowship: Memorial Sloan Kettering
20+ years clinical experience

Specializes in breast and gynecologic cancers. Author of 50+ peer-reviewed publications.

Dr. Michael Chen, MD, PhD

Radiation Oncologist
Research Director, Cancer Center
15+ years experience

Expert in precision radiation therapy and immunotherapy combinations.

Dr. Lisa Rodriguez, PharmD

Oncology Clinical Pharmacist
BCOP Certified
12+ years experience

Specializes in chemotherapy protocols and drug interaction management.

Jennifer Park, RN, OCN

Oncology Certified Nurse
MSN in Oncology Nursing
18+ years clinical experience

Expert in symptom management and patient education.

Our Editorial Process

  1. Topic Selection: Based on patient needs, search trends, and medical importance
  2. Research: Comprehensive review of medical literature, guidelines, and clinical trials
  3. Writing: Content created by medical writers with oncology expertise
  4. Medical Review: Board-certified oncologist reviews for accuracy
  5. Fact-Checking: Verification of statistics, drug names, and medical claims
  6. Patient Review: Assessment for clarity and accessibility
  7. Publication: Content published with clear attribution and date
  8. Updates: Regular review and updates to maintain currency

Content Standards

What We Cover

  • All major cancer types and subtypes
  • FDA-approved treatments and emerging therapies
  • Diagnostic procedures and staging systems
  • Side effect management strategies
  • Clinical trial information
  • Supportive care and quality of life

What We Don't Do

  • Provide personalized medical advice
  • Recommend specific treatment plans
  • Promote unproven or alternative therapies
  • Replace professional medical consultation

By The Numbers

1,100+

Medical Articles

60+

Cancer Types Covered

200+

Drug Monographs

24/7

Content Availability

Our Commitment

We are committed to:

  • Maintaining editorial independence from commercial interests
  • Providing free access to all medical content
  • Continuously improving based on user feedback
  • Supporting health literacy and patient empowerment
  • Collaborating with patient advocacy organizations

Contact Us

We welcome feedback, questions, and suggestions from our users.

Email: [email protected]

Medical Information Requests: [email protected]

Note: We cannot provide personalized medical advice. For medical emergencies, call 911 or your local emergency number.

Transparency & Disclosure

  • Oncol.net is independently operated and funded
  • We do not accept pharmaceutical advertising
  • Our reviewers disclose potential conflicts of interest
  • Content is updated based on medical evidence, not commercial interests